Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucie Ellis

Managing Editor, In Vivo

London, UK
Lucie Ellis has been covering the ups and downs of the pharmaceutical industry since joining the Informa Pharma Intelligence team in 2012. Prior to being Managing Editor of In Vivo, Lucie was a Senior Editor at Scrip and Pink Sheet. She is responsible for the production of In Vivo’s print and online editions and also contributes feature-length articles to the publication on the topics of leadership, R&D, innovation and more.
Set Alert for Articles By Lucie Ellis

Latest From Lucie Ellis

BIO-Europe Spring 2019: RedHill Preps NDA Submission For Antibiotic Talicia

Gilead Raday, chief operating officer of RedHill Biopharma, talks to Lucie Ellis, executive editor of In Vivo, about recently published late-stage data and next steps for its antibiotic asset, Talicia (RHB-105), for the treatment of Helicobacter pylori infection. 

Clinical Trials Infectious Diseases

BIO-Europe Spring 2019: Addex CEO: There’s Space For Better Therapies In Parkinson’s

At the recent BIO-Europe Spring partnering conference, Tim Dyer, CEO of Addex Therapeutics, spoke to Lucie Ellis, executive editor of In Vivo, about the company’s small-molecule allosteric modulators for central nervous system disorders.

Companies Strategy

BIO-Europe Spring 2019: INKEF Capital: Investing In Health, Technology And The Gaps In Between

Roel Bulthuis, managing partner of INKEF Capital, talks to In Vivo’s executive editor Lucie Ellis about the group’s 500m fund and where INKEF is placing its bets in biotech.

Financing StartUps and SMEs

Building Bayer For The Next Decade And Navigating A Patent Cliff

As Bayer prepares for several of its key products to lose patent exclusivity in four to five years’ time, In Vivo caught up with the company’s new head of pharma, Stefan Oelrich, to hear more on his strategy for the future – especially his plans for drug R&D, collaboration and a pipeline built on external innovation.

C-Suite Speaks Leadership

BIO-Europe Spring 2019: Apeiron CEO On Pipeline Progress And Partnering

Peter Llewellyn-Davies, CEO and chief financial officer of Apeiron Biologics, talks to Lucie Ellis, executive editor of In Vivo, on the sidelines of the recent BIO-Europe Spring conference about the company’s pipeline and partnering strategy.

Companies ImmunoOncology

Secarna’s Antisense Sweet Spot Offers Deal And IPO Prospects

Jonas Renz, managing director of antisense platform company Secarna, discussed deal making and the company’s outlook in an interview at the recent BIO-Europe Spring partnering conference.

StartUps and SMEs Platform Technologies
See All